Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
CVS Health operates 9,000+ retail pharmacies across the US, Aetna health insurance covering 26 million medical members, and Caremark PBM processing 1.5 billion prescriptions annually. The company is vertically integrated across pharmacy services, insurance, and care delivery (1,100+ MinuteClinics, Oak Street Health primary care centers). Stock performance hinges on PBM pricing pressure, Medicare Advantage margin trends, and retail pharmacy traffic.
CVS generates revenue through three integrated channels: (1) PBM spread pricing and rebate retention on $200B+ in annual drug spend, earning $3-5 per script processed; (2) Insurance premiums and medical loss ratio management at Aetna, targeting 85-87% MLR on Medicare Advantage; (3) Retail pharmacy dispensing fees ($10-15 per script) and front-store merchandise sales with 25-30% gross margins. Vertical integration allows cross-selling (steering Aetna members to CVS pharmacies) and data monetization across the care continuum. Operating leverage is moderate due to high fixed costs in retail footprint and technology infrastructure, offset by variable pharmacy labor and drug acquisition costs.
Medicare Advantage margin compression or expansion - CMS reimbursement rate changes and medical cost trends directly impact Aetna profitability
PBM contract renewals and pricing pressure - large client losses (e.g., Centene, Blue Shield) or spread compression from transparency initiatives
Retail pharmacy script volumes and reimbursement rates - DIR fees, GER (generic effective rate) changes, and traffic trends
Oak Street Health and primary care expansion ROI - integration execution and member growth in value-based care
Regulatory risk around PBM rebate pass-through requirements and vertical integration scrutiny
PBM disintermediation risk from biosimilar adoption, direct manufacturer-to-payer contracting, and potential legislation requiring 100% rebate pass-through to plan sponsors
Medicare Advantage reimbursement pressure as CMS tightens risk adjustment coding and reduces benchmark rates to control federal spending
Amazon Pharmacy and Mark Cuban Cost Plus Drugs disrupting retail pharmacy economics through transparent pricing and mail-order penetration
UnitedHealth's Optum vertically integrated model with superior scale (90M+ members vs CVS 26M) and deeper physician network ownership
Walgreens-VillageMD and Cigna-Evernorth competing for primary care and specialty pharmacy market share
Walmart and Costco expanding pharmacy footprint with lower-cost structures and higher traffic retail destinations
Elevated debt/EBITDA of ~3.5x from $70B Aetna acquisition requires $10B+ annual FCF for deleveraging, limiting M&A flexibility and dividend growth
Goodwill impairment risk on $80B+ intangible assets if Medicare Advantage or PBM profitability deteriorates structurally
Pension and OPEB obligations of $5B+ underfunded, requiring ongoing cash contributions
low - Healthcare spending is non-discretionary with 70%+ of revenue from government programs (Medicare, Medicaid) providing stable demand. Prescription volumes are largely inelastic to GDP fluctuations. Front-store retail (~10% of revenue) has modest sensitivity to consumer spending, but pharmacy services and insurance are recession-resistant.
Rising rates increase financing costs on $50B+ debt load (weighted average ~4.5% cost of debt), adding $50-100M in annual interest expense per 100bps increase. Higher rates also compress valuation multiples for low-growth healthcare stocks trading on FCF yield. Conversely, CVS benefits from higher investment income on insurance float ($20B+ in cash and investments at Aetna). Net impact is moderately negative as debt service outweighs float income.
Moderate exposure through Aetna's insurance operations - economic downturns can increase Medicaid enrollment (lower reimbursement rates) while reducing higher-margin commercial membership. Unemployment spikes shift mix toward government programs. PBM business has minimal direct credit risk as CVS doesn't extend consumer credit, but client bankruptcies could impact receivables.
value - Trading at 0.2x P/S and 7.8% FCF yield, CVS attracts deep value investors betting on operational turnaround, PBM margin stabilization, and debt paydown. Dividend yield of 4%+ appeals to income-focused funds. Activist investors (e.g., Glenview Capital) have pushed for strategic alternatives including potential breakup of integrated model.
moderate - Beta of ~0.8 reflects defensive healthcare characteristics, but stock experiences sharp moves on earnings misses, regulatory headlines, and PBM contract losses. 52-week range typically 30-40% wide due to binary outcomes on Medicare Advantage bids and large client renewals.
